Beam Therapeutics reports base editing proof of concept in GSDIa trial

BEAM-301 enabled two patients to fast for 15 hours and eliminate starch supplementation entirely after a single dose, Beam said at ESGCT 2026.

Beam Therapeutics reports base editing proof of concept in GSDIa trial

Beam Therapeutics has presented initial Phase 1/2 clinical data for BEAM-301, its investigational base editing therapy for glycogen storage disease type Ia (GSDIa), at the European Society of Gene and Cell Therapy's 33rd Annual Congress in Hamburg. The company said the results demonstrate proof of concept for in vivo genetic correction of the disease's underlying R83C mutation, with two patients in the 40 mg cohort achieving full elimination of their daily cornstarch regimen after a single intravenous infusion.

GSDIa is a rare autosomal recessive disorder caused by mutations in the G6PC1 gene that disable glucose-6-phosphatase, the enzyme responsible for maintaining blood glucose between meals. Without it, patients can enter hypoglycaemic shock within one to three hours of fasting and must consume cornstarch multiple times a day to maintain safe glucose levels. BEAM-301 uses a lipid-nanoparticle delivery system to carry base editing reagents directly to liver cells, where they rewrite the R83C point mutation without making double-stranded breaks in the DNA.

Trial data

As of the 17 August 2026 data cutoff, six patients had been dosed across two cohorts: three at 20 mg and three at 40 mg, with a median follow-up of 7.6 months. The headline measure was time to fasting hypoglycaemia (TTH), a validated index of endogenous glucose production. In the 20 mg cohort, median TTH rose from 2.9 hours at baseline to 4.3 hours by Day 36. In the 40 mg cohort the improvement was substantially greater, rising from 2.5 hours at baseline to 15.0 hours, the protocol-defined maximum controlled fasting duration. Two of three patients in that cohort also reduced their daily starch intake by 100% and had not resumed supplementation at their latest assessment. Continuous glucose monitoring showed increased time in the euglycaemic range without a corresponding rise in hypoglycaemic episodes.

On safety, four of six patients experienced serious treatment-emergent adverse events considered related to BEAM-301, including three Grade 3 infusion-related reactions. Beam attributed these partly to the shorter-acting steroid premedication used in this patient population and said dosing and infusion-rate protocols have since been modified. Two further serious events, diarrhoea and rhabdomyolysis, resolved without sequelae. Transaminase elevations were mostly Grade 1 and resolved without intervention; total bilirubin remained within normal limits throughout. No dose-limiting toxicities were reported.

Enrolment in the 60 mg cohort is now underway, and Beam said it plans to engage the FDA on a potential approval pathway.

Market context

The GSDIa space has historically attracted limited therapeutic investment given the small patient population, but the disease's severity and the clear genetic target have made it well suited to precision editing approaches. Beam is not alone in targeting the condition: gene replacement strategies using adeno-associated virus vectors have been explored in earlier research, though none has yet reached late-stage pivotal trials. BEAM-301's base editing approach differs from conventional gene therapy in that it aims to correct the endogenous sequence rather than deliver a functional gene copy, a distinction regulators and payers are likely to scrutinise closely.

More broadly, the LNP-delivered base editing modality now has a small but growing clinical evidence base. Beam's results in GSDIa complement earlier data in haematological indications, and will be watched by the wider gene editing sector as an indicator of how durable single-dose in vivo correction proves to be over longer follow-up periods. Investors will be attentive to the 60 mg cohort readout and any signal from the FDA engagement on what a pivotal study design might look like.

John Evans, chief executive of Beam Therapeutics, said the results show the company is "generating important clinical proof of concept for BEAM-301 in GSDIa and once again demonstrating the potential of base editing to fundamentally change the treatment paradigm for patients."